

## Commentary

# Adolescent Vaccination in India: Recommendation from the Indian Association for Adolescent Health

Sunanda Gupta<sup>1</sup>, Jugal Kishore<sup>2</sup>, Pallavi Boro<sup>3</sup>

<sup>1</sup>Senior Resident, <sup>2</sup>Director Professor & HOD, Department of Community Medicine, VMMC and Safdarjung Medical College, New Delhi, India.

<sup>3</sup>Assistant Professor, Department of Community Medicine, Tomo Riba Institute of Health and Medical Sciences, Naharlagun.

DOI: <https://doi.org/10.24321/2349.2880.202211>

## I N F O

### Corresponding Author:

Pallavi Boro, Department of Community Medicine, Tomo Riba Institute of Health and Medical Sciences, Naharlagun.

### E-mail Id:

[boropallavi@gmail.com](mailto:boropallavi@gmail.com)

### Orcid Id:

<https://orcid.org/0000-0001-5625-2870>

### How to cite this article:

Gupta S, Kishore J, Boro P. Adolescent Vaccination in India: Recommendation from the Indian Association for Adolescent Health. *Ind J Youth Adol Health.* 2022;9(4):1-4.

### IAAH Expert Members:

Dr. Khrist Roy, Dr. Manisha Gohel, Dr. Manju Toppo, Dr. OP Rajoura, Dr. Pratap K Jena, Dr. Pawan Goel, Dr. Ravneet Kaur, Dr. Sonia Puri, Dr. Salil Dube, Dr. Sneha Kumari, Ms. Seema Rani, Dr. Swati Sharma, Dr. Tanu Anand.

Date of Submission: 2022-11-30

Date of Acceptance: 2022-12-29

In 2019, India's top ten causes of death included ischaemic heart disease, chronic obstructive pulmonary diseases, stroke, diarrhoeal diseases, neonatal diseases, lower respiratory tract infection, tuberculosis, diabetes, cirrhosis, falls, road injuries, and self-harm.<sup>1</sup> It is noticeable that some of the causes or risk factors of the above-mentioned conditions are vaccine-preventable in nature.

To date, no specific immunisation schedule has been adopted by the Government of India for adolescents. The Indian Academy of Pediatrics recommends immunisation in adolescents under the categories of mandatory vaccines, catch-up vaccines, and vaccines in special situations.<sup>2</sup>

The all-age group HBsAg seroprevalence was reported to be 2.9% (2.6 to 3.3). The death rate was 7.9 (6.4 to 9.7) per 100,000 population (all age groups included).<sup>3</sup> There is a recent resurgence of diphtheria cases in the past few years in India.<sup>4-6</sup> In a recent systematic review from India, the overall seroprevalence rate of VZV infection in the general population of India was 72.48% (95% CI; 68.21%-76.56%).<sup>7</sup> In multisite surveillance between 2016 and 2018, influenza was found to be the most common virus detected among acute respiratory infection (15.4%; 95% CI: 14.5-16.2) and severe acute respiratory infection (12.7%; 95% CI: 11.9-13.5) cases.<sup>8</sup> In a modelling study, it was estimated that 0.56 million (0.49-0.64 million) severe episodes of pneumococcal pneumonia and 105 thousand (92-119 thousand) pneumococcal deaths occur in India.<sup>9</sup> A meta-analysis from India reported the prevalence of laboratory-confirmed typhoid among individuals with fever across all hospital studies to be 9.7% (95% CI: 5.7%-16.0%).<sup>10</sup> In recent years, many measles outbreaks have been reported among adolescents and adults.<sup>11-13</sup> A review article from the Indian subcontinent revealed the changing trend in the endemicity of hepatitis A infection, with more susceptible adolescents/ adults than previously observed. Older age groups were reported to present with more severe symptoms of hepatitis A.<sup>14</sup>

There is no specific data about the burden of hepatitis A among Indian adults and the cost-effectiveness of the vaccine.<sup>15</sup> No study is available

for testing the cost-effectiveness of influenza vaccine in low-middle income countries.<sup>16</sup> However, Indian consensus-based recommendations for influenza vaccine include vaccination of people who are living with, or caring for high-risk people; pregnant women; older adults (aged more than 50 years); people with chronic medical conditions; and children.<sup>17</sup> For the yellow fever vaccine, the average out-of-pocket expenditure was found to be INR 2153 per person, with a range varying from INR 400 to INR 26950 equivalent to USD 6 to USD 380 according to 2022 rates.<sup>18</sup> In the World Health Organization (WHO) South-East Asia Region, only three countries accounted for 98% of the total reported malaria cases in the region, the primary contributor being India (58%). India also represents 3% of the global malaria burden.<sup>19</sup> Cost-analysis of malaria vaccination is yet to be conducted in India. Evidence from Indian studies suggests that adolescent vaccination with the human papillomavirus vaccine, pre-exposure prophylaxis of rabies vaccine, hepatitis B virus vaccine, typhoid vaccine, pneumococcal vaccine, and dengue vaccine are cost-effective interventions for addressing the burden of the disease.<sup>20-25</sup> For malaria, measles, mumps, rubella, yellow

fever, meningococcal infection, influenza, chicken pox, and hepatitis A, no cost-effective analyses are available in India.

In one of the estimations by Sujitha et al., it was found that pre-exposure prophylaxis against rabies was 20 times less than the cost of PEP (Post-Exposure Prophylaxis), therefore it would be a highly cost-effective strategy if instituted among children and adolescents.<sup>21</sup> Pre-exposure rabies prophylaxis is safe and immunogenic and should be considered where the risk of exposure is high. Not just cost-effective, pre-exposure prophylaxis is also effective considering the challenges of post-exposure prophylaxis in India.<sup>26,27</sup> Children and adolescents are more exposed to pet animals during their play and providing post-exposure prophylaxis to every exposed child is difficult.<sup>28</sup> A wide multi-centre survey in India showed that 35.3% of the total human rabies cases belonged to the age group of 14 years or less.<sup>29</sup>

The Indian Medical Association has recommended various vaccines for adolescents.<sup>30</sup> After the consultation with Indian Association for Adolescent Health, the vaccines shown in Table 1 have been recommended during 10-19 years of age.

**Table 1. Vaccines Recommended for Adolescents**

Vaccine	Doses	Route	Schedule
Hepatitis A	3	IM	0-1-6 months
Hepatitis B	2 (killed) 1 (live attenuated)	IM	0-6 months
dT/ Tdap	1	IM	10-18 years, followed by a booster every 10 years
Varicella (chickenpox)	2	IM	4-6 weeks interval
HPV	2 (9-14 yrs) 3 (> 14 yrs)	IM	2 doses: 0-6 months 3 doses: 0-1 (HPV2), 2 (HPV4) and 6 months
Influenza	1	IM	Yearly
Pneumococcal (PPSV)	2	IM	5 years apart in high-risk persons
PCV 13	1	IM	6-18 yrs, if not received previously and having some medical conditions e.g., HIV, sickle cell disease, CKD
Typhoid	1 (conjugated)		Till 18 years, repeat every 3 years in case of unconjugated vaccine
MMR	2	SC	4-8 weeks interval, only one dose if previously vaccinated
Japanese encephalitis	1	IM	Till 18 years of age (in endemic areas)
Meningococcal (ACWY)	1 or 2	IM	A single dose (not high risk), 2 doses 4 weeks apart in high-risk persons
Rabies	3 or 4	ID/ IM	Pre-exposure: 0, 7, 28 days Post-exposure: 0, 3, 7, 28 days

## Way Forward

The Scientific Advisory Group of Experts (SAGE) has suggested an Expanded Programme of Immunization (EPI) that expands immunisation activities beyond infancy, especially till adolescence.<sup>31</sup> The immunisation schedule needs to be expanded for adolescents, only after rigorous cost-analysis studies in India. In the absence of robust evidence of cost-effectiveness, the suggested vaccines may not be advisable under the national immunisation schedule. Keeping in mind the need of the hour, nationwide studies for estimation of the cost-effectiveness of these vaccines must be prioritised and encouraged.

A vaccine in adolescents is contraindicated when there was a severe allergic reaction (e.g., anaphylaxis) after the previous dose of that particular vaccine. In case of mild to moderate allergic reactions, strict precautions should be observed. In the case of live vaccines such as MMR, adolescents with severe immunodeficiency (e.g., long-term immunosuppressive therapy, receipt of chemotherapy, or severely immune-compromised patients with HIV infection) may defer the vaccination.

It is advised to the policymakers and health managers that the investment in adolescent vaccination could be considered one of the most cost-effective public health strategies as observed in vaccinations against smallpox, polio, influenza, and other important diseases.

**Conflict of Interest:** None

## References

1. Global burden of 369 diseases and injuries in 204 countries and territories, 1990-2019: a systematic analysis for the. Global burden of disease study 2019. *Global Health Metrics* 2020; 369 (10258): p1204-1222 ([https://www.thelancet.com/journals/lancet/article/PIIS0140-6736\(20\)30925-9/fulltext](https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(20)30925-9/fulltext)).
2. IAP Guidebook on Immunization 2018-2019: by advisory committee on. Jaypee Brothers Medical Publishers; 2019.
3. GBD 2019 Hepatitis B Collaborators. Global, regional, and national burden of hepatitis B, 1990–2019: a systematic analysis for the Global Burden of Disease Study 2019. *Lancet Gastroenterol Hepatol*. 2022 Sep;7(9):796-829. [PubMed] [Google Scholar]
4. Maramraj KK, Latha ML, Reddy R, Sodha SV, Kaur S, Dikid T, Reddy S, Jain SK, Singh SK. Addressing reemergence of diphtheria among adolescents through program integration in India. *Emerg Infect Dis*. 2021 Mar;27(3):953-6. [PubMed] [Google Scholar]
5. Phalkey RK, Bhosale RV, Joshi AP, Wakchoure SS, Tambe MP, Awate P, Marx M. Preventing the preventable through effective surveillance: the case of diphtheria in a rural district of Maharashtra, India. *BMC Public Health*. 2013 Apr 8;13(1):317. [PubMed] [Google Scholar]
6. Sangal L, Joshi S, Anandan S, Balaji V, Johnson J, Satapathy A, Haldar P, Rayru R, Ramamurthy S, Raghavan A, Bhatnagar P. Resurgence of diphtheria in North Kerala, India, 2016: laboratory supported case-based surveillance outcomes. *Front Public Health* [Internet]. 2017 [cited 2023 Mar 26];5:218. Available from: <https://www.frontiersin.org/articles/10.3389/fpubh.2017.00218> [PubMed] [Google Scholar]
7. Patrikar S, Vashisht S. Seroprevalence of varicella zoster virus for India: a systematic review and meta analysis. 13th IEA SEA Meeting and ICPH - SDev [Internet]. 2018 [cited 2023 Mar 26]. Available from: <http://conference.fkm.unand.ac.id/index.php/ieasea13/IEA/paper/view/894> [Google Scholar]
8. Chadha M, Prabhakaran AO, Choudhary ML, Biswas D, Koul P, Kaveri K, Dar L, Chawla SM, Jadhav S, Bhardwaj SD, Laserson K, Saha S, Potdar V. Multisite surveillance for influenza and other respiratory viruses in India: 2016–2018. *PLOS Glob Public Health*. 2022 Nov 4;2(11):e0001001. [PubMed] [Google Scholar]
9. Farooqui H, Jit M, Heymann DL, Zodpey S. Burden of severe pneumonia, pneumococcal pneumonia and pneumonia deaths in Indian states: modelling based estimates. *PLoS One*. 2015 Jun 18;10(6):e0129191. [PubMed] [Google Scholar]
10. John J, Van Aart CJ, Grassly NC. The burden of typhoid and paratyphoid in India: systematic review and meta-analysis. *PLoS Negl Trop Dis*. 2016 Apr 15;10(4):e0004616. [PubMed] [Google Scholar]
11. Bajaj S, Bobdey P, Singh N. Measles outbreak in adults: a changing epidemiological pattern. *Med J DY Patil Univ*. 2017 Sep 1;10(5):447. [Google Scholar]
12. Karade S, Sen S, Sashindran VK, Sharma P, Kanitkar M. Measles, mumps, and rubella: a cross-sectional study of susceptibility to vaccine-preventable diseases among young people in India. *Med J Armed Forces India*. 2019 Jan;75(1):70-3. [PubMed] [Google Scholar]
13. Rathi P, Narendra V, Sathiya V, Kini S, Kumar A, Sana N, Rohini, Kamath VG. Measles outbreak in the adolescent population - matter of concern? *J Clin Diagn Res*. 2017 Aug;11(8):LC20-3. [PubMed] [Google Scholar]
14. Agrawal A, Singh S, Kolhapure S, Hoet B, Arankalle V, Mitra M. Increasing burden of hepatitis A in adolescents and adults and the need for long-term protection: a review from the Indian subcontinent. *Infect Dis Ther*. 2019 Dec 1;8(4):483-97. [PubMed] [Google Scholar]
15. Faujdar DS, Kaushik SK, Sharma P, Yadav AK. Need to study the health impact and economics of adult vaccination with India in focus. *Indian J Community Med*. 2022 Dec;47(4):471. [PubMed] [Google Scholar]
16. Peasah SK, Azziz-Baumgartner E, Breese J, Meltzer MI,

- Widdowson MA. Influenza cost and cost-effectiveness studies globally – a review. *Vaccine*. 2013 Nov 4;31(46):5339-48. [PubMed] [Google Scholar]
17. Dhar R, Ghoshal AG, Guleria R, Sharma S, Kulkarni T, Swarnakar R, Samaria JK, Chaudhary S, Gaur SN, Christopher DJ, Singh V, Abraham G, Sarkar A, Mukhopadhyay A, Panda J, Swaminathan S, Nene A, Krishnan S, Shahi PK, Sarangdhar N, Mishra N, Chowdury SR, Halder I, Katiyar SK, Jain VK, Chawla R, Koul PA. Clinical practice guidelines 2019: Indian consensus-based recommendations on influenza vaccination in adults. *Lung India*. 2020 Aug;37(Suppl 1):S4-18. [PubMed] [Google Scholar]
  18. Pasi A, Dan A, Gaikwad P. Out of pocket expenditure for yellow fever vaccination - an experience from a new established yellow fever vaccination centre at Thoothukudi, Tamil Nadu. *Int J Health Sci Res*. 2019;9(7):19-23.
  19. World Health Organization [Internet]. Malaria; [cited 2022 Jun 23]. Available from: <https://www.who.int/india/health-topics/malaria>
  20. Chauhan AS, Prinja S, Srinivasan R, Rai B, Malliga JS, Jyani G, Gupta N, Ghoshal S. Cost effectiveness of strategies for cervical cancer prevention in India. *PLoS One*. 2020 Sep 1;15(9):e0238291. [PubMed] [Google Scholar]
  21. Sujitha P, Swetha NB, Gopalkrishnan S. Cost analysis of rabies prophylaxis in India. *Int J Community Med Public Health*. 2020;7(9):3403-8. [Google Scholar]
  22. Phadke A. Cost-efficacy and effectivity of hepatitis-B vaccination. Centre for Enquiry into Health and Allied Themes.
  23. LB-5213 - Field effectiveness of a typhoid conjugate vaccine - Navi Mumbai (India), 2018-2020 [Internet]; 2020 [cited 2022 May 22]. Available from: <https://www.abstractsonline.com/pp8/#!/9181/presentation/4739>
  24. Krishnamoorthy Y, Eliyas SK, Nair NP, Sakthivel M, Sarveswaran G, Chinnakali P. Impact and cost effectiveness of pneumococcal conjugate vaccine in India. *Vaccine*. 2019 Jan 21;37(4):623-30. [PubMed] [Google Scholar]
  25. Krishnamoorthy Y, Majella MG. Economic evaluation and budget impact analysis of dengue vaccination following pre-vaccination serological screening in India. *Vaccine*. 2020 Jul 14;38(33):5154-62. [PubMed] [Google Scholar]
  26. Royal A, John D, Bharti O, Tanwar R, Bhagat DK, Padmawati RS, Chaudhary V, Umamathi R, Bhadola P, Utarini A. A cost-effectiveness analysis of pre-exposure prophylaxis to avert rabies deaths in school-aged children in India. *Vaccines (Basel)*. 2022 Dec 30;11(1):88. [PubMed] [Google Scholar]
  27. Haradhanalli RS, Hanumanthaiah AN, Varadappa ST. Cost of rabies post exposure prophylaxis in different healthcare settings in six states of India. *Indian J Public Health*. 2019 Sep;63:44. [PubMed] [Google Scholar]
  28. Kessels JA, Recuenco S, Navarro-Vela AM, Deray R, Vigilato M, Ertl H, Durrheim D, Rees H, Nel LH, Abela-Ridder B, Briggs D. Pre-exposure rabies prophylaxis: a systematic review. *Bull World Health Organ*. 2017 Mar 1;95(3):210-9C. [PubMed] [Google Scholar]
  29. Sudarshan MK, Madhusudana SN, Mahendra BJ, Rao NS, Narayana DH, Rahman SA, Meslin FX, Lobo D, Ravikumar K, Gangaboraiah. Assessing the burden of human rabies in India: results of a national multi-center epidemiological survey. *Int J Infect Dis*. 2007 Jan;11(1):29-35. [PubMed] [Google Scholar]
  30. Indian Medical Association [Internet]. Life Course Immunization Guide; 2018 [cited 2022 Dec 24]. Available from: [https://www.ima-india.org/ima/pdfdata/IMA\\_LifeCourse\\_Immunization\\_Guide\\_2018\\_DEC21.pdf](https://www.ima-india.org/ima/pdfdata/IMA_LifeCourse_Immunization_Guide_2018_DEC21.pdf)
  31. Verma R, Khanna P, Chawla S. Adolescent vaccines: need special focus in India. *Hum Vaccin Immunother*. 2015;11(12):2880-2. [PubMed] [Google Scholar]